Syncom Formulations Stock Screener | Share Price & Fundamental Analysis

SYNCOMF Pharmaceuticals
Share Price NSE
₹13.11
▲ 0.86 (7.02%)
2026-04-08 00:00:00
Share Price BSE
₹13.11
▲ 0.86 (7.02%)
2026-04-08 00:00:00
Track Syncom Formulations share price live with TickJournal's free stock screener. Analyze Syncom Formulations share price history trends and compare 52-week high low levels. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Syncom Formulations Market Cap ₹1,090.40 Cr.
SYNCOMF P/E Ratio (TTM) 15.48
Syncom Formulations P/B Ratio 2.81
EPS (TTM) ₹0.57
Dividend Yield -
Debt to Equity 0.12
SYNCOMF 52 Week High ₹18.11
Syncom Formulations 52 Week Low ₹10.30
Operating Margin 18.00%
Profit Margin 15.70%
SYNCOMF Revenue (TTM) ₹121.00
EBITDA ₹27.00
Net Income ₹19.00
Total Assets ₹413.00
Total Equity ₹342.00

Syncom Formulations Share Price History - Stock Screener Chart

Screen SYNCOMF historical share price movements with interactive charts. Analyze price trends and patterns.

Syncom Formulations Company Profile - Fundamental Screener

Screen Syncom Formulations company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SYNCOMF shares.
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
ISIN INE312C01025

Syncom Formulations Balance Sheet Screener

Screen SYNCOMF balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2025 2024 2023 2022 2017 2016 2015
Assets
Total Assets 413 405 378 308 180 175 138
Current Assets 270 275 182 140 83 86 79
Fixed Assets 125 120 91 94 55 46 46
Liabilities
Total Liabilities 0 0 0 0 0 0 0
Current Liabilities 12 10 9 8 8 6 6
Non-Current Liabilities 0 0 0 0 0 0 0
Shareholders' Equity
Total Equity 342 288 256 222 117 109 100
Share Capital 94 94 94 86 78 78 78
Reserves & Surplus 248 194 162 131 39 31 22

Syncom Formulations Income Statement Screener - Profit & Revenue Analysis

Screen Syncom Formulations income statement and profit fundamentals. Analyze SYNCOMF quarterly results, revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Syncom Formulations share price evaluation.
Item 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Mar 2023-Jun 2023-Sept 2023-Dec 2022-Mar 2022-Jun 2022-Sept
Revenue 121 127 123 156 132 107 89 78 68 62 68 70 64 54 57
Expenses 94 103 101 131 113 90 77 65 55 53 57 58 56 48 50
EBITDA 27 24 22 25 19 16 12 13 13 8 10 12 8 7 7
Operating Profit % 18.00% 15.00% 14.00% 12.00% 12.00% 12.00% 12.00% 13.00% 10.00% 11.00% 10.00% 11.00% 3.00% 7.00% 8.00%
Depreciation 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1
Interest 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1
Profit Before Tax 25 22 20 23 17 15 10 10 10 6 8 9 6 5 5
Tax 6 5 5 6 4 4 3 3 2 2 2 2 1 1 2
Net Profit 19 17 16 18 13 11 8 7 9 4 7 7 5 4 4
EPS 0.23 0.18 0.21 0.16 0.14 0.16 0.11 0.10 0.10 0.07 0.08 0.09 0.05 0.03 0.06

Syncom Formulations Cash Flow Screener - Liquidity Fundamentals

Screen SYNCOMF cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March 2022-March 2017-March 2016-March 2015-March
Operating Activities 23 -6 11 16 14 24 0
Investing Activities -18 83 -45 -27 -18 -23 1
Financing Activities -68 -15 35 8 5 -2 1
Net Cash Flow -63 63 1 -3 1 -1 2

Syncom Formulations Shareholding Pattern Screener

See Syncom Formulations shareholding pattern with promoter, FII, and DII holdings. Check Syncom Formulations promoter holding and ownership changes for SYNCOMF on TickJournal.
Item 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec
Promoter Holding 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57%
FII Holding 0.11% 0.41% 0.10% 0.26% 0.08% 0.09% 0.10% 0.13%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 45.20% 44.83% 45.21% 45.04% 44.85% 45.08% 45.14% 45.06%
Other Holding 4.12% 4.19% 4.12% 4.13% 4.50% 4.27% 4.18% 4.24%
Shareholder Count 484,529 471,066 457,364 442,280 325,761 376,530 469,242 489,520

Syncom Formulations Share Dividend Screener - Share Yield Analysis

Check Syncom Formulations dividend history with payout and yield data. View Syncom Formulations dividend details including ex-dates and amounts for SYNCOMF stock.
Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹0.00 0.00%
2024-March ₹0.00 0.00%
2023-March ₹0.00 0.00%
2022-March ₹0.03 0.50%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Syncom Formulations Stock Index Membership

See which indices include Syncom Formulations stock. Check SYNCOMF index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE INDEX BSE HC
BSE INDEX SMLCAP

Syncom Formulations Market Events Screener - Corporate Actions

Get Syncom Formulations corporate actions including splits, bonuses, and buybacks. Check Syncom Formulations stock events that may affect SYNCOMF share price.
Announcement Date Record Date Event Type Information Price Impact
Annual General Meeting NA -8.54%
Annual General Meeting NA -7.00%
Annual General Meeting NA -5.18%
Dividend ₹ 0.03 /share 0.00%
2026-02-12 2026-02-12 Quarterly Result Announcement NA 6.51%
2025-11-12 2025-11-12 Quarterly Result Announcement NA -0.62%
2025-08-08 2025-08-08 Quarterly Result Announcement NA -0.72%
2025-05-19 2025-05-19 Quarterly Result Announcement NA 6.39%
2025-02-10 2025-02-10 Quarterly Result Announcement NA 0.00%
2024-11-11 2024-11-11 Quarterly Result Announcement NA -1.63%

Syncom Formulations Competitors Screener - Peer Comparison

Screen SYNCOMF competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 401,025 37.12 54,729 9.71% 10,980 37.98
Divis Laboratories 153,945 62.72 9,712 18.67% 2,191 33.24
Torrent Pharmaceuticals 134,197 59.42 11,539 6.99% 1,911 32.75
Lupin 102,250 22.29 22,910 13.74% 3,306 47.35
Dr Reddys Laboratories 100,307 18.40 33,741 16.73% 5,725 39.36
Cipla 95,165 21.27 28,410 7.12% 5,291 26.86
Zydus Life Science 86,189 17.30 23,511 18.55% 4,615 41.42
Mankind Pharma 82,090 45.73 12,744 20.90% 2,007 41.40
Aurobindo Pharma 77,165 22.27 32,346 9.43% 3,484 64.38
Alkem Laboratories 61,845 25.95 13,458 3.70% 2,216 42.54

Syncom Formulations Company Announcements - News Screener

Screen SYNCOMF latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-04-07 Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A -
2026-03-25 Closure of Trading Window -
2026-02-13 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-02-12 Regulation 33(3) Of SEBI (LODR) Regulations 2015 - Submission Of Standalone & Consolidated Unaudited Financial Results Along With Limited Review Report For The Quarter And Nine Months Ended On 31St December 2025 -
2026-02-04 Board Meeting Intimation for Intimation Of Holding 5/2025-26 Board Meeting For Consideration And Approval Of The Standalone And Consolidated Unaudited Financial Results For The Quarter Ended On 31St December 2025. -
2026-01-08 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-01-08 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-01-03 Pursuant To Regulation 30 Read With Schedule III Part A Of SEBI (LODR) Regulations 2015 -
2025-12-26 Closure of Trading Window -
2025-11-22 Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015 Read With Master SEBI Circular SEBI/HO/CFD/Pod2/CIR/P/0155 Dated 11Th November 2024. -
2025-11-13 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2025-11-12 Regulation 33(3) Of SEBI (LODR) Regulations 2015 - Submission Of Standalone & Consolidated Unaudited Financial Results . -
2025-11-12 Board Meeting Outcome for Regulation 33(3) Of SEBI (LODR) Regulations 2015 Submission Of Standalone & Consolidated Unaudited Financial Results Along With Limited Review Report -
2025-11-07 Board Meeting Intimation for Board Meeting Intimation -
2025-10-16 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2025-10-01 Announcement under Regulation 30 (LODR)-Change in Management -
2025-10-01 Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association -
2025-10-01 Announcement under Regulation 30 (LODR)-Change in Management -
2025-10-01 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2025-10-01 Shareholder Meeting / Postal Ballot-Scrutinizers Report -